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Abstract 
Background: Associating liver partition with portal vein ligation for staged-hepatectomy 
(ALPPS) is a technique for inducing accelerated hypertrophy in patients with insufficient 
future liver remnant (FLR). It remains unknown whether this hypertrophy may lead to rapid 
cancer cell dissemination and/or alteration of immune cell/function reconstitution in the 
FLR. We aimed to determine if the rapid hypertrophy during ALPPS procedure results in 
more circulating tumour cell (CTCs) dissemination and whether the FLR remains 
immunologically competent in patients with CRLM.   
Methods:  In our prospective, observational, 2-arm study, we assessed the utility of CTCs 
as an evaluation tool for disease dissemination. Moreover, mucosa-associated invariant T 
(MAIT) cells were used as a marker of liver immune competency of the FLR in patients 
undergoing to ALPPS (Arm-1) or single stage liver resection (Arm-2; control) from July 
2015-June 2016. Blood samples and liver tissue were collected at different time points. 
CTCs were measured by the CellSearch System. CTC positivity was defined as > 1 CTCs 
in a 7.5-ml blood sample. Frequency of MAIT cells were measured in both groups (blood, 
liver and tumour) using flow cytometry.  
Results Among 24 potential patients, 17 met the criteria and underwent curative hepatic 
resection: 7 in Arm-1 and 10 in Arm-2. Baseline demographics were similar between 
groups. In stage-1 ALPPS, CTCs were present in two patients (28.6%), one of whom 
continued to be positive after completion of both stages, whereas four patients (44.4%) in 
Arm-2 were positive, p=0.289. Patients with positive CTCs (one each-Arms) at follow up 
developed early recurrence and died, p=0.0083.  In addition, we found a trend towards an 
increase in MAIT cells within the liver in Arm-1 compared to Arm-2 (28 %vs17.42%; 
respectively), (p=0.067), and within the tumor (17.42%vs10.42%, respectively, p=0.308).  
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Conclusion: Accelerated and extensive liver hypertrophy during ALPPS was not 
associated with CTC dissemination. Persistent positivity of CTCs at follow-up was 
significantly associated with disease progression and cancer-related death. Presence and 
upward trend in the frequency of the MAIT cells in the ALPPS group suggest immune cell 
restoration in the FLR. Nevertheless, given the small sample size, a larger cohort is needed 
to validate these findings.  
Keywords: Circulating tumor cells (CTCs), Associating liver partition with portal vein 
ligation for staged hepatectomy (ALPPS), colorectal liver metastases (CRLM), CellSearch 
System, the mucosa-associated invariant T (MAIT) cells. 
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CHAPTER 1 
1. INTRODUCTION 
1.1. Colorectal Cancer Incidence 
Colorectal cancer (CRC) represents the third most common cancer world-wide with 
about ~1.4 million new cases in 2012 and the fourth leading cause of death, ~700,000 
annually (8.5%). (1,2) The countries with the highest incidence rates are Australia, New 
Zealand, Canada, the United States, and some countries in Europe such as the UK; whereas 
China, India, Africa, and South America have the lowest incidence. (1,3) In Canada,  CRC 
is the second most common type of cancer among males (13.9%), and the third most 
common type of cancer in females (11.5%), representing the third most common overall 
types of cancer (12.7%). (4) 
 
1.2. Colorectal Liver Metastases (CRLM) 
The liver is a common site for hematogenous metastases from CRC. (5–8) Up to a 
fifth of patients with primary colorectal carcinoma have synchronous hepatic metastases, 
and nearly half of  patients who undergo resection of their primary CRC will develop with 
will develop metachronous liver metastases at some time during the course of their 
disease.(9) 
 
1.3. Treatment 
1.3.1. Systemic Treatment for CRLM 
The outcome of untreated colorectal liver metastases (CRLM) has been well 
documented in the literature. (6,10) The median survival of untreated synchronous CRLM 
is just 5 to 10 months, and 3-year survival is very unusual, limited only to those patients 
		
2	
who initially have solitary liver metastases arising in a metachronous manner.(6) Over the 
past 3 decades, 5-fluoracil (5-FU) has been used either alone or in the combination with 
other regimens for the treatment of colorectal liver metastases. (6,11) The tumor response 
rates with 5-FU alone are reported to be 10-15%, and can reach up to 30-39% when 
Leucovorin (LV) is added. The median overall survival (OS) with 5-FU alone is reported 
to be ~12.6 months, improved to 14.8 months when combination therapy is used. (6,11) 
Currently, with the development and improvement of new chemotherapy regimens 
such as irinotecan (FOLFIRI) and oxaliplatin (FOLFOX), the tumour response rate has 
improved from 22% to ~ 50%, allowing these therapies to emerge as the first line regimen 
for treatment of stage IV colorectal cancer (CRC).(5,6,12) The overall survival outcomes 
reported using these regimens has been superior to single agent therapy (19.5 months versus 
15 months) (11) without a significant difference with respect to patient tolerance or toxicity. 
Overall survival following FOLFIRI and FOLFOX treatment is similar at 21.5 and 20.6 
months respectively. (11,13) The FOLFOX regimen is complicated by an elevated rate of 
neurotoxicity and neutropenia, while FOLFIRI therapy is associated with other symptoms 
such as nausea, vomiting, mucositis, and alopecia. (6,11) 
Other therapies have emerged to target growth factors or cell surface receptors 
involved in colorectal cancer liver metastases biology. These biological therapies might 
stabilize disease and improve patient disease-free survival by causing tumour necrosis. 
(11,12) Bevacizumab (Avastin), is a monoclonal antibody against vascular endothelial 
growth factor (VEGF), approved to be used in combination with 5-FU as first-line 
chemotherapy for patients with CRLM. These regimens have demonstrated a higher tumour 
response rate and longer patient overall survival, when compared to therapies without 
Avastin therapy, 44.8 vs 34.8% and 20.3 vs 15.6 months, respectively. (12) Moreover, 
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additional monoclonal antibody therapies such as cetuximab and panitumumab have also 
shown benefit for tumors with KRAS mutation by improving the response rate and patient 
survival. (14) 
In summary, modern systemic chemotherapy has improved outcomes for metastatic 
CRC treatment and plays an important role in the absence of resection (median survival 
~18 to 20 months) (11).  However, notable and superior results are achieved when 
combined with liver resection (5-year survival ~55-67%). (15) 
1.3.2. Surgical Management of CRLM 
During the last 3 decades, hepatic surgical treatment has evolved and become the 
gold standard for patients with primary or metastatic liver malignancies. Moreover, the 
actual role of the multidisciplinary tumour board committees in the management of this 
complex group of patients, with the aim of surgical resection has achieved the most 
satisfactory results, benefiting the overall course of the patient during the disease process. 
(5,6,16). The actual 5-year survival following a margin-negative hepatic resection with the 
combination of chemotherapy treatment is ~ 40-70%, with 10-year survival approaching 
20%. (6,17,18) Recurrence and progression is reported in 70–80% patients undergoing 
surgery. (5) In addition, the notable ability of the liver to regenerate after hepatic resection 
has enabled aggressive surgical approaches in patients with insufficient hepatic reserve.  
Resectability criteria for CRLM patients have been widely revised and expanded 
over the last 15 years. (5) Previous clinic pathological parameters such as number or 
metastases, presence of extra-hepatic disease or width of resection margin are no longer 
used to exclude patients from consideration for surgical resection. (5–7) The current hepatic 
resection criteria should be defined by: the preservation of vascular inflow, vascular 
outflow, and biliary drainage, with the objective of preserving an adequate future liver 
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remnant (FLR). Those patients with extensive liver disease or borderline liver parenchyma 
reserve should undergo a technique to increase the volume of their FLR such as portal vein 
embolization (PVE), two-stage hepatectomy, or a chemotherapy modality to downsize the 
disease and convert the liver tumor burden into resectable disease.(5) 
As described in the literature, for the best outcomes, surgical resection should only 
be considered if the following criteria are met: (6–8,19) 
1. Adequate patient health performance condition (normal baseline lung, heart, kidney 
and liver function). 
2. Primary tumour resectable or already resected. 
3. Absence of extra-hepatic disease, or if present and localized, disease is planned for 
resection (e.g. lung metastases). 
4. Solitary nodule or multiple nodules technically feasible for liver resection (attempt 
to get negative resection margins “R0”).  
5. Vascular inflow and outflow with adequate biliary drainage in the remaining liver 
must be preserved. 
6. Adequate volume/function of the FLR after resection (at least 20% of the total FLR 
if normal parenchyma and 30-70% when a history of chemotherapy or underlying 
liver disease is present).(19,20) 
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1.3.2.1. Future Liver Remnant (FLR) 
Over the past two decades, there has been an inclination to expand what is defined 
as “resectable” disease, pushing the boundaries and leaving a narrow line between complete 
success and liver failure. Therefore, development of new multidisciplinary modalities has 
been explored to improve the resectability rate while avoiding catastrophic post 
hepatectomy liver failure (PHLF). Reports recommend an estimated FLR to body weight 
ratio of greater than 0.5 to avoid liver failure. (20,21)  
To achieve an adequate volume of the FLR after resection and thus, decrease the 
risk of developing PHLF, patients with normal liver parenchyma or undergoing a short 
course of chemotherapy (< 12 weeks) usually require a FLR of at least >20 %, while a FLR 
>30-60% is needed for patients after >12 weeks of chemotherapy, steatosis or hepatitis, and 
a FLR > 40-70% is mandatory in the presence of underlying liver disease (e.g. cirrhosis, 
cholestasis depending on the degree of underlying hepatic dysfunction). Thus, 
chemotherapy duration and adequate FLR volume are the critical determinants of hepatic 
reserve which directly affect morbidity and mortality following hepatic resection for 
CRLM. (20–23) 
 
1.3.2.2. Techniques to increase the FLR  
During the last 40 years, several surgical and non-surgical techniques have emerged 
in order to increase the size of the FLR and avoid PHLF, in those patients with primary and 
metastatic liver cancer undergoing to extensive liver resection. Examples of these 
procedures are: portal vein occlusion (either by embolization or ligation), two staged 
hepatectomy, and ALPPS (Associating Liver Partition with Portal Vein Ligation for Staged 
Hepatectomy). (7,8,13,24) 
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1.3.2.2.1. Portal Vein Occlusion (PVO) 
Makkuchi et al. introduced the use of portal vein embolization (PVE) in the early 
1980s as a non-surgical technique to stimulate hypertrophy of the FLR before extensive 
liver resections. (25) Currently, two methods of portal vein occlusion (PVO) can be applied 
and are considered as standard therapy for patients with unilobar disease and insufficient 
FLR:  either radiologically by portal vein embolization (PVE) or surgically by portal vein 
ligation (PVL). The PVO technique has been shown to increase the size of the FLR from 
8% to 27% over an interval of 2-8 weeks, depending on the underlying liver disease. 
Unfortunately, these same hypertrophy results have been difficult to replicate at other 
centers. PVO is safe, with a complication rate of 5-8%(19). However, its main 
disadvantages include insufficient hypertrophy of the FLR and disease progression after 
the PVO, preventing curative liver resection in 20-30% of patients. (26) 
 
1.3.2.2.2. Two-Stage Hepatectomy: 
The concept of two-stage hepatectomy was introduced in the early 2000s. (26) This 
surgical hepatic technique was designed for patients with primarily bilobar unresectable 
liver metastases, which typically cannot be resected in a single stage while preserving an 
adequate FLR. The strategy of the two stage hepatectomy is to attempt a curative resection 
through a sequential approach. The goal of the first stage is to clear the future liver remnant 
by removing the highest number of metastases, making the second hepatectomy feasible 
and potentially curative after proper FLR regeneration. (26) Thus, a two-stage hepatectomy 
offers the potential of disease free survival to patients that otherwise would have a poor 
outcome. Patients who undergo a two-stage hepatectomy with combination chemotherapy 
have a 3-year survival rate of 35% and a median survival of 31 months. (5,26) Nevertheless, 
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initial experience without PVE was associated with high incidence of PHLF from 
insufficient functional volume of the FLR a high mortality rate of 9-15%. (5,27) 
 
1.3.2.2.3. Two-Stage Hepatectomy with PVO 
Liver failure due to insufficient functional liver volume of the FLR represents the 
main cause of postoperative mortality in patients undergoing two-stage hepatectomy. Thus, 
the combination of PVO (either PVE or PVL) and staged hepatectomy was proposed as a 
modality to induce compensatory hypertrophy of the FLR.(27–29) After introduction, 
initial reports showed no operative mortality, low postoperative morbidity (~ 15 to 30%), 
and 1-and 3-year overall survival rates of 70% and 54%, respectively. (5,27) Nevertheless, 
insufficient liver regeneration of the FLR and tumor progression during the long waiting 
period (6-8 weeks) was again the biggest limitation, making this procedure only feasible in 
70% of the cases. (30) 
 
1.3.2.2.4. Associating Liver Partition with Portal Vein Ligation for Staged 
Hepatectomy (ALPPS) 
During a planned extended right hepatectomy for a perihiliar cholangiocarcinoma, 
ALPPS was created by chance in 2007. Due to insufficient FLR, the right portal vein was 
ligated to induce hypertrophy of the left lateral segment of the liver, after the liver 
parenchyma had already been transected. On postoperative day 8, abdominal computed 
tomography imaging showed extensive hypertrophy of the left lateral segment prompting 
the decision to complete the resection of the right liver. (23) Therefore, the new technique 
consisted of adding a liver parenchymal partition during the first stage of a two-staged 
hepatectomy, facilitating an inter-stage time of only 1 week.  
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The initial experience of this innovative technique was presented in 2011 during the 
European Hepato-Pancreato-Bilairy meeting held in South Africa.(30) Soon after, during 
the inaugural study in 2012, the authors reported their experience in 25 patients. Initially 
the procedure was named as “two-staged extended right hepatectomy with initial surgical 
exploration, right PVL, and in situ splitting” (22), and later renamed with the acronym 
“ALPPS” (Associating Liver Partition with Portal Vein Ligation for Staged 
Hepatectomy).(31) 
 
1.3.2.2.4.1. ALPPS Results Worldwide: 
Since the first description of the ALPPS procedure, refinements to both the 
technique, and patient selection criteria have been explored. The most promising results 
have been reported in the field of CRLM, and thus, establishing the main indication for 
ALPPS to be when metastases are primarily unresectable due to a very small predicted 
FLR. (7,8,30,32) Other indications to consider are in specific situations such as 
hepatocellular carcinoma (HCC) or cholangiocarcinoma, if resection is oncologically 
possible .(7) 
In terms of volumetric growth, rapid liver regeneration remains the main advantage 
of ALPPS: total liver volume growth of FLR is reported around 50-84% in 1 week and 120-
200% after 14 days. (7,32,33) Nevertheless, principle limitations are related to high 
morbidity (53–90%), high mortality (0–28%), and no reports on long-term oncologic safety 
and outcome.(8) The largest studies from the ALPPS registry report the procedure has a  
97% feasibility rate with a morbidity rate of 44%, and 90-day mortality rate of 8-
11%.(33,34) From the oncological standpoint, long-term outcomes with respect to the 
disease free and overall survival are areas that need further investigation.                                                                                                                                                                                                                                                                                                                                                
		
9	
1.3.2.2.4.2. ALPPS Results at the London Health Sciences Centre 
The first ALPPS procedure in Canada was performed in London, Ontario at the 
London Health Sciences Centre (LHSC) in April 2012 by Dr Roberto Hernandez-
Alejandro. (35) Ever since, LHSC has been the pioneer and leader overall in North 
America. Despite the high morbidity and mortality earlier described, (30) refinements in 
the technique and a better understanding of patient selection has been  paramount to success 
at our institution, in addition to our strict selection criteria: patients with colorectal liver 
metastases (CRLM), extensive bilobar CRLM necessitating an extended hepatectomy, a 
technically feasible resection (planned R0), a predicted FLR <30%, no evidence of extra-
hepatic disease, good functional capacity defined as ECOG (Eastern Cooperative Oncology 
Group) 0 or 1, and complete or partial tumour response after 6-cycles of  neo-adjuvant 
therapy assessed by  the Response Evaluation Criteria In Solid Tumors (RECIST). (35)  
Furthermore, we have paid special attention to the improvement of the surgical 
technique by maximizing the preservation of the middle hepatic vein and minimizing the 
dissection of the hepatoduodenal ligament to avoid ischemia and congestion of segment 4 
and to decrease the potential for ischemic injury to the biliary tree. Taken together, these 
points might explain our lower morbidity rate (14%) and postoperative 90-day mortality 
rate (0%) compared with other centers.(35) To date, our center has already performed 34 
ALPPS procedures and our latest data shows a 1-year OS of 84% and 3 years OS of 55% 
(median 1264 days), as well as 1-year DFS of 71%, and 3-year DFS of 36%. (Figures 1 
and 2) 
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Figure 2. ALPPS Disease-Free Survival, LHSC: LHSC 2012-2016
Median Disease Free Survival (DFS) 628 days (95% CI 298-958) 
1-year DFS 71%, 2-year DFS 41%, 3-year DFS 36%
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1.4. Liver immunology 
The liver is considered the largest solid organ in the body involved in non-
immunological activities such as metabolic functions, nutrient storage, and detoxification. 
Also, it is a place of complex immunological properties, such as induction of 
immunological tolerance and innate immune responses, which are possible through the 
production of diverse acute phase proteins, complement components, cytokines and 
chemokines, and by different populations of resident immune cells.(24,36,37) 
The liver functions impressively as an important filter for gut contents and blood 
systemic circulation via the Porto-systemic interface (70-80% of the liver blood supply 
comes from the portal vein, with the remaining 20-30% from the hepatic artery). As a low 
pressure blood system, liver venous blood flows in close contact with the hepatic sinusoids. 
Hepatocytes compose ~60-80%  of overall liver cells (38). Their main role is in metabolism, 
and production of 80–90% of the circulating innate immunity proteins in the body.(6) 
Moreover, the liver capillary microenvironment consists of different specialized cells (liver 
sinusoidal endothelial cells [LSEC],  intravascular liver resident macrophages “Kupffer 
cells”, and liver dendritic cells) which have an important role in initiating and organizing 
hepatic immune responses. 
The liver immunological homeostasis mechanism is not fully understood yet. The 
narrow balance between tolerance and liver immunity is controversial. Classical examples 
of tolerance can be observed in viral hepatitis infections, metastatic cancer (most commonly 
from colorectal cancer), and transplantation. On the other hand, undesirable immune 
responses may ensue, for instance, in the case of autoimmune hepatitis, primary sclerosing 
cholangitis (PSC), and primary biliary cirrhosis (PBC). (6,37) Figure (3) 
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Moreover, the liver has essential immune and metabolic roles that are described and 
summarized in Figure 4. The following sections will provide a basic understanding of the 
immunological mechanisms orchestrated by the liver, and focus on the role of those liver 
cells that are implicated in tumour immune surveillance (liver lymphoid cell population). 
In particular, the role of the “Mucosal-associated invariant T (MAIT) cells” will be 
discussed. 
 
1.4.1. Human liver cell distribution 
 The liver contains most of the cellular elements of the innate and adaptive 
immunity. Their frequency and distribution are observed in Figure 5. (39) Each of them 
has a specific role and effector function, either cytotoxic or regulatory, capable of killing 
pathogens or suppressing the immune response. Also, differentiation into cells that can 
produce different cytokines and antibodies, IFN (interferon), IL (interleukins), TGF 
(transforming growth factor), TNF (tumor necrosis factor) can be observed, which has an 
important role during antitumor surveillance. (6,39) 
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Figure 3. Liver Tolerance vs Immunity (6):  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Image representing liver tolerance vs immunity. The liver has tolerogenic 
characteristics observed in diseases such as viral hepatitis, metastatic cancer and transplantation. 
On the opposite side, the liver exhibits a high immune response: autoimmune hepatitis, PSC and 
PBC. From Jarnagin WR, Blumgart LH, 2012: Blumgart´s surgery of the liver, biliary tract and 
páncreas. 2-Volume set. 5E ed. Copyright 2012,2007,2000,1994,1998 by Saunders, and imprint 
of Elsevier Inc. 
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1.4.2.  Antigen-Presenting Cells: 
Antigen-presenting cells (APCs) are important in orchestrating or shaping the 
adaptive immune response. The three most important APC cells are Kupffer cells, LSEC, 
and dendritic cells. They play a crucial role in the maintenance of tolerance balance on non-
inflammatory scenarios.  The liver APC cells function in capturing and presenting antigens 
to T cells.  The success of their activation and response, depends directly on the proper 
molecular co-stimulation. If co-stimulation is successful, proliferation and development of 
effector T cells will occur, with subsequent release of cytokines. In contrast, if co-
stimulation is unsuccessful T cell death or anergy will result.  (6,38–40) 
 
1.4.3. Dendritic cells (DCs), liver sinusoidal endothelial cells and Kupffer cell 
(KCs) 
Liver DCs are known as the most potent APCs of the immune system (Figure 6,7). 
They play an essential role in the antigen capture and subsequent presentation to the 
immune effector cells. Liver DCs travel from the portal circulation through the space of 
Disse, finally exiting via lymphatic circulation. Their essential function involves immune 
regulation, bridging, and adaptive immunity. Nevertheless, liver DCs show tolerogenic 
characteristics, promoting the production of anti-inflammatory IL-10, which has a 
suppressive function. (24,37,38) 
Liver sinusoidal endothelial cells work as sentinels, and are important during 
pathogen detection. Their structure in the form of multiple fenestrations selectively allows 
the passage of antigens through the LSEC to the hepatocytes, establishing close contact 
among antigens and hepatocytes. This characteristic promotes organ homeostasis, blood 
detoxification, and inflammatory response regulation.(6,37) 
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Figure 4. Liver immunological & metabolic roles (37) : 
 
 
 
 
 
Figure 4. Metabolic and immunological roles of the liver. The liver has an important role in 
inflammatory regulation via production of clotting factors and acute phase proteins, antigen 
presenting T cells and anti-microbial proteins. In addition, it has important metabolic roles 
including lipid metabolism, glycogen storage production, protein production, and others. From 
Robinson MW, 2016: Liver immunology and its role in inflammation and hemeostasis. Cell Mol 
Immunol 13:267-76. Copyright 2016, CSI and USTC. 
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Figure 5. Healthy liver cell distribution. 
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Figure 5. Distribution and frequency of parenchymal and non-parenchymal healthy 
human liver cells. From Racanelli V,2006: The liver as an immunological organ. 
Hepatol Baltim MD 43:S54-62. Copyright 2006, The American Association for the 
Study of Liver Diseases. 
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Liver Kupffer cells originate from monocytic precursors and correspond to the 
largest group of macrophages in the body. Their phagocyte function and strategic location 
allow them to travel from the periportal area to the space of Disse, with subsequent 
elimination of endotoxins and apoptotic hepatocytes. (6,38,39) 
 
1.4.4. Liver Lymphoid Immune Cell Population 
The liver lymphoid cell population is composed of T cells, natural killer cells (NK 
cells), and B cells. (37,39) The main characteristics of these cells include potent cytokine 
production and mediating the innate and adaptive immune response of the liver. In addition, 
they contribute to the removal of infected, injured or malignant cells. A subpopulation 
arising from T cells comprises conventional T cells (CD8+ and CD4+), which identifies 
antigens in the context of major histocompatibility complex (MHC) class I and II. 
Typically, CD8+ is higher in proportion to CD4+ (2:1) in the liver, whereas their frequency 
is inverted in the blood. Unconventional T cells correspond to another subtype of T cells. 
These are integrated of natural killer T cells (NKT cells), which have a restricted T receptor 
and recognizes antigens only in the case of MHC I (molecule CDI d), and TCRγδ T cells, 
that identifies a very limited proportion of antigens.(6,36,37,39) 
 
1.4.5. Natural Killer Cells 
Human NK cells comprises most of the lymphocyte liver population and play an 
important role during liver inflammation, particularly in antiviral defense.  Traditionally, 
NK cells are categorized as either CD56-low-expressing cells with cytolytic activities, 
CD56-high-expressing with immune-modulatory cytokine-producing cells, and CD49a, 
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which mainly release high proportions of CD69, granzyme B, interferon-γ (IFNγ), tumour 
necrosis factor-alpha (TNF-alpha), and granulocyte macrophage colony-stimulating factor 
(GM-CSF).(24,36,41) 
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Figure 6. Innate immune liver elements: 
 
 
 
 
 
Figure 6. Image representing the microvascular hepatic anatomy. Liver sinusoidal endothelial cells 
shield and divide hepatocytes from sinusoidal blood flow by the “Space of Disse” flow.  In addition, 
DC, KC, NKT cells, NK cells can be found and have close contact with the microcirculation, and 
had a subsequent specific function in the inflammatory response. 
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Figure 7. Liver immune response. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Schematic representation of the adaptive immune response illustrating  inflammatory 
activation, from antigen-presenting cells to T and B cells leading to signaling, costimulation and 
cytokine production with subsequent effector function, From Jarnagin WR, Blumgart LH, 2012: 
Blumgart´s surgery of the liver, biliary tract and páncreas. 2-Volume set. 5E ed. Copyright 
2012,2007,2000,1994,1998 by Saunders, and imprint of Elsevier Inc. 
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1.4.6. Natural Killer T cells (NKT cells) 
NKT cells are a specific subgroup of T cells, whose main role is to regulate the 
immune responses in the environment of autoimmunity, cancer, and microbial infection, 
through the expression of different cytokines such as interleukin-4 (IL-4) and IFNγ. In the 
cancer context, tumour-infiltrating human NKT cells express CD56, CD69, and pro-
inflammatory cytokines such as TNF-alpha and IFNγ, showing an important antitumor 
role.(41,36,37) 
 
1.4.7. MAIT cells 
The study of mucosal-associated invariant T (MAIT) cells in humans is an emerging 
field in immunology. Human MAIT cells are known as a subset population of conventional 
T cells, which are localized preferentially in liver and intestinal mucosa, composing ~30-
50% of the liver lymphocytes and 10-15% of the peripheral blood lymphocytes.(42) 
Circulating and tissue-infiltrating human MAIT cells express a semi-invariant T cell 
receptor (TCR) of Vα7.2-Jα33 alpha chain rearrangement (CD161 or IL 18Rα) and respond 
to MHC I like molecule MR1 (MHC-related protein 1). (42–44) 
Emerging experimentation has shown that activated MAIT cells can display 
different cytokines such as interleukin-17A (IL-17A), IFN-γ, and TNF-αlpha. (42,43,45) 
As a subset of the innate-like T cells, MAIT cells produce an arsenal of cytotoxic effector 
molecules and pro-inflammatory cytokines that play an important function in defense 
against infectious pathogens (bacteria and yeasts, but not viruses). (43,46,47) In addition, 
they play a role in inflammatory diseases and wound healing by their quick reactivity to 
bacterial infection and injury. (43,46,47) These distinguishing characteristics have 
prompted the immunology community to question their potential role in certain 
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circumstances such as cancer. Despite this, yet we know next to nothing about their role in 
immune surveillance against tumor formation in the liver. Recent evidence has suggested 
that they may have potential clinical relevance for patients with colorectal cancer.(44) 
Moreover, further investigations demonstrate their peculiar ability to persist through  
chemotherapy  and xenobiotics secreted by the gut bacteria (42),  due at least in part  to 
their high levels of ABCB1 expression, which works as a multidrug efflux protein 
transporter to remove toxic compounds from the cytoplasm.(42,43)  
 
1.4.7.1. MAIT Cells in Colorectal Cancer 
Results presented in early 2016 by a group from China (44) suggest that MAIT cells 
accumulated and infiltrated in CRC tumour tissue, and thus might play an important role in 
immune surveillance against CRC patients (Figure 8). Their study showed that the 
frequency of circulating activated/memory MAIT cells was lower compared with the levels 
observed in the tumour tissue. Furthermore, serum carcinoembryonic antigen (CEA) levels 
were found to be highly associated with the rate of infiltrating MAIT cells and negatively 
associated with the rate of circulating active/memory MAIT cells. In fact, high levels of 
TNF-α, IFN-γ, IL-2 and IL-17 were positively associated with TCRValpha7.2Jalpha33 
mRNA in cancer tissues.(44) This data supports that high levels of infiltrating 
activated/memory MAIT cells in the tumour tissues might represent anti-tumor immunity 
against CRC, so, use as a potential biomarker for testing the severity and prognosis of CRC 
should be considered. Also, some reports demonstrated an important association between 
IFN-γ levels in the setting of T cell immunity against CRC through p53 modulation to 
induce tumor cells apoptosis (45), whereas, other studies show an associaciation between  
IL-17 expression in the tumor and  worse prognosis in patients with CRC. (48) 
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In the present investigation, we further evaluate MAIT cells in terms of their role 
on hepatic immune surveillance against colorectal liver metastases in patients undergoing 
liver resection.  
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Figure 8. Hypothetical MAIT cell role during CRLM. 
 
 
 
 
 
 
 
 
Figure 8. Schematic representation of the hypothetical role of MAIT cells during colorectal liver 
metastases. 
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1.5. Circulating Tumour Cells (CTCs) 
Cancer metastasis is the principal cause of death in patients with cancer, and 
dissemination of tumour cells into the systemic blood circulation is an essential step. 
Therefore, early identification of this dissemination sequence is crucial for monitoring and 
impeding metastatic disease. The mechanisms by which circulating cancer cells 
disseminate from the tumour to the blood circulation is an area under intensive 
investigation. (49–52)   
 
1.5.1. Natural History of Metastases from Colorectal Cancer 
Tumor metastasis can be defined as a series of biological processes whereby tumor 
cells from the primary neoplasm migrate to a distant location.(9,49,52) (Figure 9 ) Invasive 
CRC cells can metastasize through two pathways: 
1. Regional lymph nodes ® through central lymphatics ® the systemic circulation. 
2. Portal venous drainage ® Liver. 
Circulating tumour cells (CTCs) are defined as a group of cells that are shed from 
primary tumour and from metastatic deposits into the blood circulation.(49,53) CTCs are 
found in the blood of patients with many cancers, however, their presence is extremely 
infrequent in healthy people.(49,52)  The use of  CTCs as prognostic and predictive tumour 
markers has been explored in patients with metastatic cancers such breast (54–57), prostate 
(58,59) and colorectal (60,61) carcinoma. On the basis of these studies, the number of CTCs 
(≥5 for breast/prostate; ≥3 for colorectal) were predictive of progression-free survival (PFS) 
and overall survival (OS). Moreover, the analysis of CTCs at different time-points during 
treatment has been shown to be useful for determining treatment efficacy and therapy 
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response. These promising findings suggest that CTCs may represent a “liquid biopsy” that 
could inform clinical decision-making, potentially allowing for the discontinuation of 
ineffective chemotherapy regimens earlier than current practice, thereby avoiding 
morbidity due toxicity and enabling a change to other potentially more beneficial treatment 
options. (54,58) 
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Metastatic colonization includes the following process: 
1. Tumor cells invade the tissue surround the primary tumor. 
2. “Invasion” into either the lymphatics or blood circulation. 
3. Intravasion ® Extravasion ® Growing ® Angiogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1	
2	
3	
Figure 9. Schematic representation of biological process of metastatic colorectal dissemination. 
The term ‘colonization’ is used herein to reflect the combined influences of tumor cell 
proliferation, apoptosis, dormancy and angiogenesis in the formation of a progressively growing 
lesion in a distant site.(9) 
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Multiple methods for CTC enrichment and identification have emerged during the 
last decade, either label-dependent such as immunomagnetic, where the main target has 
been epithelial cell adhesion molecule (EpCAM), or label-independent enrichment based 
on size or density. Other approaches characterize CTCs by immunocytochemistry, using 
PCR approaches or mRNA/DNA sequences. Additionally, others can detect viable tumour 
cells or tumor-specific chromosomal abnormality (Figure 10). (49,62–64) 
 
1.5.2. CellSearch System 
Originally developed by Immunicon, the CellSearch system (Janssen Diagnostics, 
Raritan, NJ, USA) is the first and currently the only method clinically approved assay by 
the Food and Drug Administration (FDA) for capturing and enumerating CTCs in advanced 
breast, prostate and colorectal cancer.(54,55,59,60,64)  
The epithelial cell adhesion molecule (EpCAM) is a cell adhesion molecule 
overexpressed in many carcinomas and has been used as a marker for CTC enrichment. 
The CellSearch is a semi-automated system based on immunomagnetic technology that 
isolates and enumerates CTCs by targeting EpCAM-positive cells. Through this approach, 
CTC numbers have been correlated with disease free survival and overall survival in 
primary and metastatic carcinoma. (54,56,57,59,60) Due to its reported clinical evidence, 
high reliability, and FDA clearance, we chose the CellSearch system as a method for CTC 
detection in this research study. 
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CTC enrichment and identification approaches for CTCs (63): 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Schematic representation of different strategies to separate and capture circulating 
tumour cells: label-dependent and label-independent methods. Immunomagnetic based methods 
focusing on EpCAM protein are the most common used among label-independent CTC 
enrichment methods. From Joosse SA,  2015: Biology, detection and clinical implications of 
circulating tumor cells. EMBO Mol Med 7:1-11. Copyright The Authors. 
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1.5.3. Use of CTCs in Colorectal Malignancies 
Novel technology platforms using immunomagnetic separation have permitted the 
accurate identification, isolation, enumeration, and characterization of CTCs from many 
epithelial carcinomas. (49,52,64–66) In a multicenter study, Cohen et al reported, that 
patients with colorectal liver metastasis had unfavorable survival prognosis when levels of 
CTCs of CTCs were ³ 3 in 7.5 ml of blood, and showed that this was an independent 
predictor of inferior disease free survival and overall survival in patients with colorectal 
liver metastases. (60)  
These results provide a promising basis from which to investigate different 
scenarios of the applicability of CTCs in colorectal cancer patients; including screening in 
earlier stages of colorectal cancer, evaluation of treatment response and analysis of 
progression during the time off chemotherapy (Figure 11). Recent studies have also 
evaluated the impact of the presence of CTCs at the time of liver resection in metastatic 
colorectal cancer. (2,67–69) A Norwegian group reported the association between positive 
CTCs and high recurrence rate in patients with colorectal liver metastases undergoing two-
stage hepatectomy, suggesting another potential utility for postoperative CTC 
assessment.(2) This current study will assess the utility of measuring the number of CTCs 
as an evaluation tool of disease progression using the CellSearch system in patients with 
colorectal liver metastases undergoing for liver resection; either ALPPS or single stage 
liver resection. 
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Pathways of circulating tumour cells in patients with colorectal cancer (62): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Diagram showing the pathway of CTCs, through the mesenteric-porto-systemic 
circulation in colorectal cancer patients. Circulating tumour cell (red cells) flows from the 
primary tumour to the systemic blood, then are captured using the CellSearch system technology. 
From Deneve e, 2013: Capture of viable circulating tumor cells in the liver of colorectal cáncer 
patients. Clin Chem 59:1384-92. Copyright American Association for Clinical Chemistry. (62) 
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CHAPTER 2 
2. RATIONALE, HYPOTHESES, AND STUDY OBJECTIVES 
2.1. Rationale 
Since the first description of ALPPS procedure, refinements to both the technique 
and patient selection criteria have been developed. ALPPS has been demonstrated to be a 
valid treatment option in selected patients who were previously considered unresectable, 
especially in those with colorectal liver metastases.(7,30,35,70) Nevertheless, several 
important aspects of the procedure remain unknown, including long-term oncological 
outcomes. Moreover, concerns arise with respect to the impact of this rapid hypertrophy in 
the liver microenvironment, in particular related to potential repercussions for tumour 
biology and disease progression. In addition, the immunological composition of the liver 
during the ALPPS approach and whether the rapid hypertrophy of the FLR is accompanied 
by equally rapid immune cell/function reconstitution remains essentially unexplored.  
Circulating tumour cells are defined as a group of cells that are shed from primary 
tumour and metastatic deposits into the blood circulation.(49,53) Their use  as a prognostic 
and predictive tumour marker has been explored in patients with colorectal liver metastases 
(60,61). On the basis of these studies, the number of CTCs (≥3/7.5 mL blood) were 
predictive of inferior disease free survival and overall survival in patients with colorectal 
liver metastases. Moreover, the analysis of circulating tumour cells at different time points 
during the treatment was useful to determine treatment efficacy and therapy response, thus 
supporting the use of this novel biomarker as a tool for decision making before liver 
resection in patients with CRLM. This study aims to investigate the utility of measuring 
the number of circulating tumour cells as an evaluation tool of disease progression using 
the CellSearch system in patients with colorectal liver metastases undergoing two stage 
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hepatectomy; ALPPS or single stage liver resection. 
The liver represents a specialized immunological environment that promotes 
tolerance in normal conditions, but also contains immune cells that can potentially combat 
cancer. While tumor-specific T cells are detectable in many cancer patients including those 
with primary liver cancers or liver metastases, they typically fail to eradicate cancer. The 
liver harbors many natural killer T (NKT) cells that constitute an attractive therapeutic 
target for adjuvant immunotherapy of cancer. In addition, the liver is highly enriched in 
mucosa-associated invariant T (MAIT) cells, which can comprise up to 50% of all hepatic 
lymphocytes; yet we know next to nothing about their role in immune surveillance against 
tumors forming in the liver. MAIT cells express an arsenal of cytotoxic effector molecules 
as well as pro-inflammatory cytokines (interferon [IFN]-gamma, interleukin [IL]-17) 
known to favor antitumor immunity. It is currently unclear whether MAIT cells infiltrate 
tumor masses in the liver.(42,45) Due to these characteristics mentioned, it has prompted 
the immunology community to hypothesize on their potential role in certain circumstances, 
such as cancer. In the present investigation, we further explore the role of MAIT cells, in 
terms of immune surveillance against colorectal liver metastases in patients undergoing 
liver resection.  
 
2.2. Hypotheses 
We hypothesize that an elevation of ≥3 CTCs/7.5 ml in the blood will indicate 
disease progression during the rapid liver hypertrophy in patients with colorectal liver 
metastases. Moreover, we believe that the presence of MAIT cells with their cytotoxic 
effector molecules and pro-inflammatory cytokines such as (interferon [IFN]-gamma, 
interleukin [IL]-17) in the future liver remnant will represent the immunological 
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competency of the liver during the rapid liver regeneration process in ALPPS patients with 
colorectal liver metastases. Finally, we predict that chemotherapy will not affect the liver 
immune functions. 
 
2.3. Objectives 
1. To determine if rapid hypertrophy in colorectal liver metastases induces disease 
progression.  
2. To determine if the liver in patients with colorectal liver metastases undergoing ALPPS 
is immunologically competent. 
3. To identify if chemotherapy affects the liver immune response in patients with 
colorectal liver metastases undergoing for liver resection. 
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CHAPTER 3 
3. Methodology 
3.1. Experimental Design 
We designed a prospective, observational, 2-arm feasibility study assessed the 
utility of blood biomarkers of cancer progression (Circulating tumour cells, “CTCs”), and 
immunological competency of the liver (MAIT cells) in patients with colorectal liver 
metastases (CRLM) undergoing ALPPS (Arm 1) or single stage liver resection (Arm 2; 
control).  
Up to 10 eligible patients per arm were accrued from the London Health Science 
Centre-University Hospital (LHSC-UH) and the London Regional Cancer Program 
(LRCP). Sample size was determined based on the pilot nature of the study and our 
demonstrated ability to recruit ~14 eligible ALPPS patients/year. (35) 
Ethics approval for this study was obtained from the Western University Research 
Ethics Board for Health Sciences Research Involving Human Subjects (Approval number: 
REB106937; Appendix 1) and the Lawson Health Research Institute (R-15-360). All work 
involving the use of human samples was done in accordance with ethics guidelines 
approved by the institutional research ethics review board at Western University. Subjects 
were provided a letter of consent outlining the study details and informed written consent 
was obtained. 
 
3.1.1. Patient inclusion criteria: 
• Male and female patients over 18 years of age 
•  Confirmed diagnosis of colorectal liver metastasis (CRLM) 
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• Systemic chemotherapy treatment response 
• No evidence of extra-hepatic metastatic disease 
• Intent for curative liver surgery treatment 
Technically feasible resection (planned RO) 
 
3.1.1.1. Specific inclusion criteria for ALPPS (Arm 1):  
• Diagnosis of CRLM with predicted future liver remnant less < 30% 
• Extensive bilobar CRLM necessitating an extended hepatectomy 
• Good functional capacity (Eastern Cooperative Oncology Group [ECOG] 0 or 1) 
• Complete or partial response to systemic chemotherapy after 4-6 cycles evident by 
CEA and radiology 
• Consented for ALPPS 
 
3.1.1.2. Specific inclusion criteria for single stage liver resection (Arm 2):  
• Diagnosis of CRLM with predicted future liver remnant more than > 50 % 
• Single or oligo CRLM consented for single stage resection 
 
3.1.2. Exclusion Criteria:  
• Age more than 75 or less than 18 years 
• ASA risk score more than 3 
• Eastern Cooperative Oncology Group (ECOG) score 2 or more 
• End-stage liver disease 
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3.2. Chemotherapy treatment 
 
All patients in this study were reviewed by a multidisciplinary tumor board 
(consisting of HPB and colorectal surgeons, medical oncologists, radiation oncologists, 
pathologists, and radiologists). Following discussion, the consensus recommendation of the 
multidisciplinary tumour board was followed regarding liver surgical approach and type of 
neo-adjuvant treatment regimen. The choice of chemotherapy regimen was based on 
tumour load, tolerance, and comorbidities by the multidisciplinary tumour board. Tumour 
responses and progression were classified with the use of the Response Evaluation Criteria 
in Solid Tumour (RECIST) after 4 cycles.(71) 
 
3.3. Surgical technique 
The technical aspects of single or two staged hepatectomy “ALPPS” have been 
previously described (Figures 12-14). (7,8,72–74) Major liver resection was defined 
according to the Brisbane 2000 terminology (resection  of ³ 3 segments of the liver ). (75)  
Single staged hepatectomy was performed in all patients with curative intent with 
predicted future liver remnant (FLR) more than ³ 50 %, whereas ALPPS was performed in 
those patients with predicted FLR  < 30 % that met full inclusion criteria. In both scenarios 
a general laparotomy was performed to rule out extrahepatic disease, an intraoperative 
ultrasound was performed to assess the technical resectability and presence of metastases 
not visualized prior to surgery. The liver was mobilized according to the location of the 
tumour and segments to be respected. (7) 
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The technical aspects of ALPPS procedure are summarized in two major surgical 
stages and one interval phase. The key points of stage-1 include complete mobilization with 
ligation and division of the retro-hepatic veins draining into the inferior vena cava (IVC), 
tumour clearing of the FLR if disease was present in the FLR, right portal vein ligation with 
hepatic arterial flow preservation and biliary drainage of the deportalized liver (DL), and 
liver in situ split of the parenchyma between the FLR and deportalized liver. After sufficient 
growth of the FLR is obtained (generally within 7 to 10 days) measured by volumetric 
computed tomography (CT) volumetric, a stage-2 procedure was completed with a right 
trisectionectomy by a transection of the right hilar plate, as well as transection of the right 
and middle hepatic veins followed by the removal of the DL. 
Complications were scored according to the Dindo-Clavien grading system. (76) 
Minor complication was defined as a complication grade £ II, major complication as a 
grade ≥ IIIa, and severe complications as grade ≥IIIb. 
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Figure 12. Representation of extensive metastatic bilobar disease from colorectal cancer patients.  
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Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy 
“ALPPS” concept, surgical technique description: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7-10	
Days	
Figure 13. Stage 1 ALPPS: (A) Clearing of the future liver remnant (resection of CRLM in 
segment II and III of the liver) (B) portal vein ligation in order to redirect the portal blood 
flow through the FRL with preservation of the right hepatic artery; (C) parenchymal 
transection along the deportalized liver and future liver remnant. Following by 7-10 days 
until FLR growing. 
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Figure 14. (A) Inter-stage ALPPS: volumetric liver of the FLR is reassessed at day 7-10 by abdominal 
computed tomography for enough hypertrophy; (B) Stage 2 ALPPS: ALPPS finalized with an extended 
right hepatectomy, keeping a growth FLR.  
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3.4. Circulating tumour cells (CTCs) 
Blood samples (7.5 ml) were collected by routine phlebotomy, and measured at the 
following endpoints: 
• Arm 1: baseline (pre-chemotherapy), pre- stage 1 ALPPS, inter-stage ALPSS, post 
2 stage ALPPS and prior to re-starting chemotherapy (follow-up). (Figure 15) 
• Arm 2: baseline (pre-chemotherapy), pre-resection surgery (single stage liver 
resection), 3-4 days’ post-resection surgery and prior to re-starting chemotherapy 
(follow-up). (Figure 16) 
 
3.4.1. Blood sample preparation for CellSearch® platform analysis 
Samples were collected into CellSave blood collection tubes (Janssen Diagnostics), 
which stabilize CTCs for 96 hours at room temperature. 1 x 10 ml sample per patient was 
collected at each time point. Blood samples were analyzed for the presence and number of 
CTCs using CellSearch® platform (Janssen Diagnostics) located in the clinical flow 
cytometry facility at LHSC. An automated and standardized immunomagnetic cell 
enrichment of CTCs in blood samples (7.5. ml) was carried out using antibodies targeting 
epithelial cell adhesion molecule (EpCAM), and subsequent labeling with fluorescent 
antibodies specific for epithelial cells (CK 8,18, and 19), DAPI, and leukocytes 
(CD45/DAPI). Samples were imaged using the CellSearch Analyzer II, and CTCs were 
identified by two trained (independent and blinded) reviewers based on positive CK 
staining, negative CD45 staining, cell size (> 4um), cell morphology (round to oval), and 
staining with the DNA stain 4’, 6-diamino-2-phenylindole (DAPI).  
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Figure 15. ARM 1: ALPPS group, with the sequential description of the time-points, where the CTCs 
blood samples and the liver tissue with respect to the MAIT cells were taken.  
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Figure 16. ARM 2: Single stage liver resection group, with the sequential description of the time-points, 
where the CTCs blood samples and the liver tissue with respect to the MAIT cells were taken.  
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3.4.2. Circulating tumour cell data analysis 
CTCs # at each time point were categorized as being either unfavourable (≥3 CTCs) 
or favourable (<3 CTCs) as defined previously. (60) The relationship between CTC # and 
clinical outcome was investigated and were observed and compared during the rapid liver 
regeneration process and the single liver resection. (Objective 1) 
 
3.4.3. Statistical analysis 
The distribution of continuous variables was tested for normality using the Shapiro-
Wilk test. Continuous variables with normal distributions were express as mean (± standard 
deviation) and were compared using the independent sample t-test. Variables with non-
normal distributions were expressed as median (interquartile range) and were compared 
using the Mann-Whittney-U test. Categorical variables were compared using the Fisher’s 
exact test. Statistical significance was accepted at p< 0.05. Data was analyzed using SPSS 
20 (IBM SPSS, Chicago, IL., USA). 
 
3.5. Mucosa-associated invariant T (MAIT) cells 
For the immunological studies, liver tissues and blood samples were collected from 
each Arm of the study at the time of the surgery. (Figure 15 and 16) 
3.5.1. Human peripheral blood mononuclear cell isolation 
Peripheral blood was collected prior to administration of anesthesia in 5 x standard 
heparinized BD vacutainers (BD Biosciences, San Jose, CA, USA) for a maximum volume 
of approximately 50mL). Following collection, whole blood was diluted 1:1 in 2% Fetal 
Calf Serum (FCS) /PBS and applied to a Ficoll-Paque Plus (GE Healthcare Life Sciences, 
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Mississauga, ON, CAN) gradient in 50mL SepMate tubes (Stem Cell Technologies) and 
processed at room temperature as per the manufacturers protocol. Following isolation, cells 
were resuspended in complete RPMI and seeded at approximately 1x106 cells/well in 
200µL, and indicated stimuli were added in a volume of 50µL for a total volume of 250µL 
per well.   
 
3.5.2. Human liver mononuclear cell isolation 
During the surgical resection, a 1-5 g sample of healthy liver tissue and 1-5 g sample 
of tumour tissue were collected in saline in a 15 mL tube and placed on ice. Samples were 
taken to the laboratory of Microbiology & Immunology located in the SDRI building at 
Western University. Immune function and profiling experiments were undertaken to 
determine the status of the immune cells residing within and distal to the tumour, and within 
the healthy liver tissue as well. 
Following collection, liver tissue was cut into small pieces using a razor blade, after 
which they were pushed through a 400 µM filter and washed with 2%FCS/PBS. Collected 
cells were spun at 400Xg for 5 minutes, the supernatant decanted, and the pellet washed 
with an additional 50 mL 2% FCS/PBS. Following the second wash, cells were applied to 
a 33% Percoll Plus (GE Healthcare Life Sciences, Mississauga, ON, CAN) mixture and 
spun for 12 minutes at 700Xg (no brake). Following the spin, the supernatant was 
discharged and the mononuclear cells were isolated from the pelleted fraction. Following 
isolation, cells were resuspended in cRPMI and plated at approximately 1x106 cells/well in 
200µL,  and indicated stimuli  were added in 50 µL of media for a total volume of 250µL 
per well.   
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3.5.3.  In vitro stimulation 
Recombinant IL-12 (Peprotech, Quebec, CAN) and IL-18 (Peprotech, Quebec, 
CAN) were used at a concentration of 5 ng/mL for the in vitro activation of isolated MNCs. 
The bacterial superantigen staphylococcal enterotoxin B (SEB) was used at 100 ng/mL. 
Isolated MNCs were plated at 10x106cells/mL and left untreated or stimulated with a 
combination of recombinant IL-12 (rIL-12) and rIL-18, SEB, or Klebsiella pneumoniae 
lystate for 24 hrs. For the last 5 hours, a combination of 1 µM brefeldin A (BFA) (Sigma-
Aldrich) and 2 µM monensin (eBioscience) was added to the cells.  
 
3.5.3.1.  Staphylococcal Enterotoxin B (SEB) 
Recombinant SEB was generated using an approved institutional biosafety protocol 
adhering to the Public Health Agency of Canada regulations. SEB was cloned from S. 
aureus (strain COL), expressed in BL21 (DE3) competent Escherichia coli (E. coli), and 
purified by nickel column chromatography.  
 
3.5.3.2.  Preparation of Klebsiella lysate 
A stock of Klebsiella pneumoniae lysate was generated by growing a Klebsiella 
pneumoniae clinical isolate, Parkwood-18 (a gift from Dr. Miguel Valvano (Queen’s 
University Belfast, Belfast, United Kingdom)), overnight in Luria broth at 37°C. Following 
overnight culture, the culture was washed three times with cold PBS and the OD600 adjusted 
to 6.5. Cells lysis was achieved by subjecting the cells to a pressure at 30,000 pounds per 
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square inch (PSI) for 5 min to induce membrane rupture. The resulting lysate was stored at 
-80°C until use.  The lysate was at 1:50 for in vitro cell stimulatio 
3.5.4. Flow cytometry 
Cells were labeled using various panels of anti-human antibodies, as has previously 
been described.(77) Cells were then stained extracellularly with a panel of anti-human 
antibodies at 4°C cells diluted in 2%FCS/PBS. After 30 minutes, cells were washed 3 times 
with 2 mL of 2% FCS/PBS. In cases of intracellular cytokine, 5 hrs prior to the end of 
culture a mixture of BFA diluted 1:10000 and Monensin A diluted 1:1000 (eBioscience) 
were added to the cultures to allow for the intracellular accumulation of cytokines. 
Additionally, for intracellular antigen or transcription factor analysis determination, 
following extracellular staining cells were re-suspended in 150 µL cytofix/permeabilization 
buffer (eBioscience) and left at room temperature in the dark for 20 minutes. Following 
fixation, cells were washed with 100 µL of 1x Permwash (eBioscience) and re-suspended 
in 100 µL of a panel of intracellular antibodies diluted in 1x Permwash. In the case of 
transcription factor determination, the foxP3 transcription factor permeabilization kit was 
used (eBioscience) in place of the standard intracellular cytofixation kit. A BD FACSCanto 
II flow cytometer and FlowJo v9 software (Tree Star, Ashland, OR, USA) were used for 
data acquisition and analysis.  
Human MAIT cells were defined as CD3+ Va7.2+ CD161high. Briefly our gating 
strategy was as follows: From total PBMCs, lymphocytes (defined by their forward and 
side scatter properties) were gated and divided into CD3+ and CD3-. Of the CD3+ cells, 
MAIT cells were defined as CD3+ Va7.2+ CD161high, while conventional T cells were 
considered CD3+ Va7.2-. For specific analytic analysis (i.e. cytokine, transcription factor 
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expression, granzyme, etc.), appropriate isotype controls were used when determining the 
gate locations.  Unless otherwise stated, antibodies were obtained from eBioscience. Va7.2 
-PercpCy5.5 and granzyme A - Alexa 700 were obtained from Biolegend (San Diego, CA, 
USA).  
3.5.5. MAIT cells data analysis 
Comparison of the MAIT cells present within and outside metastatic lesions in 
terms of their frequency and function (i.e. IFN- and IL-17 production) within the peripheral 
blood and liver were performed. Moreover, we evaluated the liver immunological 
competence regarding the activity of the MAIT cells among patients undergoing for rapid 
hypertrophy (ALPPS) and single liver resection was also made. (Objective 2) 
A correlation between the type of chemotherapy and the activity of the MAIT cells in the 
peripheral blood and the liver was performed in order to analyze the effect of the 
chemotherapy into the liver immune response in both groups. (Objective 3) 
 
3.5.6. Statistical analyses 
Statistical assessments were made with the aid of GraphPad Prism 6 software. 
Comparisons were performed using Student’s t-test or ANOVA, as appropriate, and 
differences with p<0.05 were deemed significant. *, **, *** and **** denote p<0.05, 
p<0.01, p<0.001 and p<0.0001, respectively. 
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CHAPTER 4 
4. RESULTS 
The objectives of the current study were to determine if the rapid hypertrophy that 
occurs during ALPPS induces disease progression, to evaluate if the liver of ALPPS 
patients was immunologically competent, and to investigate whether chemotherapy affects 
the liver immune response in patients with colorectal liver metastases undergoing for liver 
resection; either ALPPS or single stage hepatectomy. 
In our prospective, observational, 2-arm feasibility study we were able to assess the 
utility of CTCs as an evaluation tool of disease progression and the immunological 
competency of the liver through analysis of MAIT cells in patients with colorectal liver 
metastases undergoing to ALPPS (Arm 1) or single stage liver resection (Arm 2; control).  
In the present investigation (From August 2015 to June 2016), 24 patients were recruited 
for the study and 17 patients full met our study criteria; 7 patients in Arm 1 (ALPPS group) 
and 10 patients in Arm 2 (Single stage liver resection group).  Patient selection and 
management flow chart is shown in Figure 17. 
Patient characteristics from the 17 patients that completed liver resection are 
summarized in Table 1. Median follow up was 139 days (interquartile [IQR] range 46 to 
379 days). All patients completed follow-up evaluation to assess CTCs at time point 4 (1-
2 month after surgery). Demographic characteristics were comparable in both groups, 
including age, gender and body mass index. Preoperative risk index was also similar in 
both groups. 
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Flow chart of the 24 patients recruited in the study for CTC and MAIT cells 
 
 
Figure 17. Flow chart summarising the 24 patients recruited in the study for investigation of CTCs and 
MAIT cells in patients with CRLM undergoing for curative liver resection treatment, either; ALPPS (ARM1) 
or single staged resection (ARM2). Seven patients completed both stages in ARM 1, while 10 patients 
completed single staged resection in ARM 2.  
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TABLE 1. TRANSLICH STUDY POPULATION CHARACTERISTICS 
 
 
VARIABLE 
 
ARM 1  
ALPPS 
N= 7 
ARM 2  
SINGLE STAGE  
LIVER 
RESECTION 
N= 10 
 
 
p=  0.05 
Demographics 
Age, (years) µ 
Male Gender [n(%)] 
BMI (Kg/m2) µ 
 
ASA operative risk, n(%) 
      < 3 
> 3 
 
Primary tumour location, n (%) 
      Colon 
      Rectum 
 
Stage of  primary disease, n (%) 
          T-4 
          T-3 
          T-2 
       
Lymph Nodes Positive 
       
Grade, n (%) 
              High grade 
              Low grade 
 
Metastatic tumour disease, n (%) 
      Synchronous 
      Bilobar tumour involvement 
      Number of lesions 
      Size, largest lesion (mm) before chemotherapy 
      Size, largest lesion (mm) after chemotherapy 
 
Carcinoembryonic Antigen (CEAµ,mL) 
 
57 ± 4 
6 (85%) 
25 ± 2 
 
 
2 (29%) 
5 (71%) 
 
 
7 (100%) 
0 
 
 
3 (43%) 
3 (43%) 
1 (14%) 
 
4 (0-18) 
 
 
2 (29%) 
5 (71%) 
 
 
6 (85%) 
4 (40%) 
4 (2-9) 
45 (20-200) 
25 (17-150) 
 
23 (23-80) 
 
55± 3 
4 (40%) 
24.7 ± 1.3 
 
 
6 (60%) 
4 (40%) 
 
 
7 (70%) 
3(30%) 
 
 
4 (40%) 
6 (60%) 
0 
 
0.5 (0-8) 
 
 
1 (10%) 
9 (90%) 
 
 
8 (80%) 
4 (67%) 
3 (2-8) 
34.5 (10-86) 
27(10-49) 
 
4 (1-4220) 
 
0.598 
0.134 
0.969 
 
 
 
0.334 
 
 
0.227 
 
 
 
 
0.434 
 
 
0.183 
 
 
0.536 
 
 
 
1..0 
0.608 
0.599 
0.215 
0.43 
 
0.047 
Continues variables are expressed as median (IQR). Abbreviations: µ, mean; Kg, Kilograms, 
BMI, body mass index 
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4.1. Demographics Characteristics 
4.1.1. Primary Tumor Characteristics 
Primary tumour location was as follows: Arm 1; 100% of the patients had the 
primary tumour in the colon, and Arm 2; 70% (7 patients) had the primary tumor in the 
colon and 30% (3 patients) in the rectum, p= 0.334. Based on the TNM score classification 
for malignant tumours, the primary cancers in both Arms were comparable (Table 1).  
 
4.1.2. Metastatic Tumour Disease 
Synchronous metastatic disease was present in 6 patients (85%) in Arm 1 vs 8 
patients (80%) in Arm 2, p= 1.0.  Bilobar tumour involvement was observed in 4 patients 
(57%) in Arm 1 compared to 4 patients (40%) in the Arm 2, p= 0.608. The median number 
of liver metastatic lesions in Arm 1 was 4 (interquartile range [IQR] 2-9) and 3 in Arm 2 
(2-8), p= 0.599 (Table 1).  
The median size of the largest lesion (mm) before chemotherapy treatment was 45 
mm (20 mm-200 mm) in Arm 1 and 34.5 mm (10 mm-86 mm) in Arm 2, p=0.215.  After 
chemotherapy treatment, there was a decrease in the median size of previous largest lesion; 
25 mm (17 mm-150 mm) in Arm 1 and 27 mm (10 mm-49 mm) in Arm 2, p= 0.430 (Table 
1). 
The levels of Carcinoembryonic Antigen (CEA µ mL) before chemotherapy 
treatment was significantly higher in the Arm 1, 23 (23-80) compared to Arm 2, 4 (1-4220), 
p=0.0478 (Table 1). 
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4.1.3. Chemotherapy Characteristics 
Of the 17 patients that underwent liver resection, all received neo-adjuvant 
chemotherapy treatment. Patients received either single regimen with FOLFOX or 
combined regimen FOLFOX or FOLFIRI with Bevacizumab. Most of the patients in Arm 
1 had combined regimen 5/7 (71%), while most of the patients in the Arm 2 had single 
regimen with FOLFOX  7/10 (70%), p= 0.095. The median number of chemotherapy cycles 
was 6 (5-11) in Arm 1 vs 5 (1-7) in Arm 2, p=0.439. The median time off (days) 
chemotherapy prior liver resection was 50 days (32-72 days) in Arm 1 and 51 days (27-184 
days) in Arm 2, p=0.830 (Table 2). Of the 7 patients in Arm 1, 6 (86%) showed 
radiologically chemotherapy response, compared to 7 of 10 patients (70%) in Arm 2, 
p=0.338 (Table 2). 
 
4.1.4. Surgical approach  
One patient in Arm 1 (14%) underwent an extra hepatic simultaneous resection (low 
anterior resection, LAR), whereas 3 patients (30%) in Arm 2 (2 patients had LAR and 1 
patient had an abdominal perineal resection, APR), p= 0.198 (Table 3). The estimated 
blood loss in Arm 1 was significantly higher compared with Arm 2, median of 1000 ml 
(400ml-2500ml) vs 205 ml (50ml-7000ml), respectively, p= 0.013.  However, the number 
of patients that received blood transfusion was similar in both Arms, 2 each, p =1.0. The 
range of red blood cells packs per patient was .8 (0-4) in Arm 1 vs 0.9 (0-7) in Arm 2, 
p=0.933. 
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TABLE 2. TRANSLICH STUDY POPULATION CHEMOTHERAPY CHARACTERISTICS 
 
VARIABLE 
ARM 1 
 ALPPS 
N= 7 
ARM 2  
SINGLE STAGE  
LIVER RESECTION 
N= 10 
 
p=  0.05 
Chemotherapy characteristics 
      Chemotherapy prior surgery, n (%) 
      ³ 6 Cycles chemotherapy 
  
Type of chemotherapy 
     Single Regimen 
             FOLFOX 
     Combined regimen 
            FOLFOX or FOLFIRI /Bevacizumab 
 
Time off chemotherapy prior  
to liver resection (days) 
 
 
Chemo-response, radiology n (%) 
    
 
7(100%) 
6 (5-11) 
 
 
 
2 (29%) 
 
5 (71%) 
 
 
50 (32-72) 
 
 
6 (86%) 
 
10 (100%) 
5 (1-7) 
 
 
 
7 (70%) 
 
3 (30%) 
 
 
51 (27-184) 
 
 
7 (70 %) 
 
NS 
0.439 
 
 
 
 
0.095 
 
 
 
0.830 
 
 
0.338 
 
Continues variables are expressed as median (IQR). Abbreviations: single regimen, refers to single 
regimen either FOLFOX, FOLFIRI; combined regimen, refers to combination either  FOLFOX or 
FOLFIRI with Bevacizumab. 
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TABLE 3. TRANSLICH STUDY POPULATION SURGICAL CHARACTERISTICS 
 
VARIABLE 
 
ARM 1  
ALPPS 
N= 7 
ARM 2  
SINGLE STAGE  
LIVER 
RESECTION 
N= 10 
 
p=  0.05 
Type of liver resection, n (%) 
     Extended hemihepatectomy 
     Hemihepatectomy 
     ³ 3 wedges resected 
 
Extrahepatic simultaneous procedures, n (%) 
     Low Anterior Resection 
     Abdominal perineal resection 
 
7 (100%) 
0 
0 
 
 
1 (14%) 
0 
 
0 
5 (50%) 
5 (50%) 
 
 
2 (20%) 
1 (10%) 
 
 
0.002 
 
 
 
 
0.198 
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4.1.5. Future Liver Remnant (ALPPS group) 
The median interval phase in days between the two stages in the Arm 1 was 9 (7-40 
days). Of the 7 patients in Arm 1, the mean %FLR/total liver volume prior the stage one 
was 20  ± 2.2. The percentage  hypertrophy of FLR/Total liver volume after stage 1 was 35 
± 1.6.(Table 4) 
4.1.6. Surgical Outcomes 
4.1.6.1. Complications 
Six of 7 patients in Arm 1 (85%) had post-surgical complications versus 4 of 10 in 
Arm 2 (40%), p=0.050. Of these 6 complications in Arm 1, 66% were minor complications 
and 17% were major or severe complications, while in Arm 2 these values were, 25%, 50%, 
25%, respectively, p=0.405. The total length of hospital stay was significantly higher in 
Arm 1 due the fact of two stage procedure, 17.5 days (14-33) in Arm 1 compared with 7 
days (4-62 days) in Arm 2, p=0.020 (Table 5). 
4.1.6.2. Liver histopathology  
R0 resection was presented in 85% of the cases in Arm 1 and 100% of the cases in 
Arm 2. The median resection margin was significant higher in Arm 1, 20 mm (8mm -55 
mm) compared with Arm 2, 5 mm (1mm-14mm), p= 0.009.  Based on the histopathology, 
all 7 patients in Arm 1 (100%) showed chemotherapy response, versus only 5 patients 
(50%) in Arm 2, p=0.026. Also, the rate of tumour necrosis related with the chemotherapy 
response was higher in Arm 1; 80 (75-100) vs 5 (0-100) in Arm 2, p=0.009 (Table 5). 
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TABLE 4.  LIVER VOLUME ALPPS GROUP 
VARIABLE ARM 1 ALPPS 
N= 7 
 
Interval Phase in days, median (range) 
 
% Future Liver Remnant/Total liver volume (SD) 
 
% Future Liver Remnant/Total liver volume after stage 1, mean (SD) 
 
9 (7-40) 
 
20 ± 2.2 
 
35 ± 1.6 
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TABLE 5. TRANSLICH STUDY POPULATION POSTOPERATIVE  OUTCOMES 
 
VARIABLE 
ARM 1 
 “ALPPS” 
N= 7 
ARM 2  
SINGLE STAGE 
 LIVER RESECTION 
N= 10 
P=  0.05 
Complications 
     Any complications, n (%) 
 
          Minor complications, Grade £ II 
          Major complications, Grade IIIa 
          Severe complications, Grade ³ IIIb 
 
90 days’ mortality 
Mortality 
       
Total length of hospital stays in days, 
 Median (range) 
 
Histopathology liver  
     Margins (mm) 
     Chemotherapy response, n % 
     Chemotherapy, tumour necrosis % (range) 
     R0 
     R1 
 
6 (85%) 
 
4 (66%) 
1 (17%) 
1 (17%) 
 
0 
3/7 (43%) 
 
17.5 (14-33) 
 
 
 
30 (8-55) 
7 (100%) 
80 (75-100) 
6 (85%) 
1 (15%) 
 
4 (40%) 
 
1 (25%) 
2 (50%) 
1 (50%) 
 
0 
2/10 (20%) 
 
7 (4-62) 
 
 
 
5 (1-14) 
5 (50%) 
5 (0-100) 
10 (100%) 
0 
 
0.050 
 
 
0.405 
 
 
 
NS 
 
0.020 
 
 
 
0.009 
0.026 
0.009 
0.411 
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4.2. Circulating tumour cells 
Evaluation of CTC status in the 24 patients recruited in the study is summarized in 
Table 6. Due to logistical challenges, CTCs were only assessed in 2/10 patients prior to the 
start of chemotherapy in Arm 1 and in 5/14 patients in Arm 2. The findings showed positive 
CTCs in 1 (50%) patient of Arm 1 (1-4 cells), and 3 (50%) patients in Arm 2 (1-6 cells), 
p= 0.999. Moreover, assessment of CTC status was performed after completed 
chemotherapy for all of the 24 patients recruited in the study; 10/10 patients in Arm 1 and 
14/14 in Arm 2. At this time-point, none of the 10 patients in Arm 1 showed positive CTCs 
cells, whereas 2/14 (15%) patients in Arm 2 had positive CTCs (1-5 cells), p= 0.266. 
Furthermore, one patient with positive CTCs, ³3 (5 cells) in Arm 2 after completion of 
chemotherapy was found to have progression of disease on imaging and was  therefore 
withdraw from the study, p=0.0012 (Table 6). 
From the 24 patients that initiated the study, 17 completed liver resection, 7 patients 
in Arm 1 and 10 patients in Arm 2, and CTC status was evaluated after stage 1 (time-point 
3a) and stage 2 (time-point 3b) in the case of Arm 1, and compared with the control group 
of single stage liver resection in Arm 2. Among the 7 patients with CTCs available after 
stage 1, two (28.6%) patients had positive CTCs (1-2 cells), and one (17%) patient 
presented with positive CTCs (1 cell) after completing both stages. On the other hand, 4 
(44%) patients in Arm 2 presented with positive CTC status (1-2 cells), after completed 
single staged resection, p=0.286 (Table 6) (Figure 18).  
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TABLE 6.   Circulating tumour cell assessment of the 24 patients recruited for the study. 
Group Liver metastases CTCs  Time-Points Outcome 
ARM 1 Sync 
 
N of 
lesio
ns 
Size 
prior 
chemo 
(mm) 
Size 
After 
chem
o 
(mm
) 
CEA 
(µ/M
L) 
# 
Chemo 
Cycles 
Type 
of 
Chemo 
1 2 3a 3b 4 Death 
 
1 
2 
    3¯ a 
    4¯ b 
5 
6 
7 
    8¯ b 
9 
10 
Yes 
Yes 
No 
No 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
4 
9 
4 
3 
2 
2 
7 
4 
3 
3 
20 
22 
32 
26 
96 
90 
45 
20 
200 
20 
18 
22 
32 
26 
65 
46 
25 
15 
150 
17 
80 
6.2 
2 
5.4 
- 
26 
65 
102 
80 
8.3 
11 
6 
3 
12 
5 
6 
5 
6 
6 
6 
F/B 
FX 
Cap 
FX 
FR/B 
FX 
FX/B 
FR 
FX/B 
FX/B 
- 
- 
- 
- 
- 
- 
- 
- 
4 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
2 
¯ 
¯ 
0 
0 
0 
¯ 
1 
0 
0 
-d 
¯ 
¯ 
0 
0 
0 
¯ 
1 
0 
0 
1 
¯ 
¯ 
0 
0 
-d 
¯ 
0 
0 
Yes 
YesR 
¯ 
¯ 
No 
No 
Yes 
¯ 
No 
No 
ARM 2   1 2  3 4  
11 
12 
13 
   14¯ c 
15 
16 
17 
18 
19 
     20¯ b 
     21¯ b 
22 
23 
   24¯ c 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
Yes 
5 
3 
8 
3 
4 
2 
2 
6 
4 
2 
4 
4 
2 
2 
14 
13 
34 
85 
35 
45 
16 
86 
10 
30 
40 
47 
48 
58 
10 
18 
19 
120 
35 
35 
14 
49 
15 
40 
40 
45 
48 
58 
4.3 
4.1 
28.1 
16 
- 
2.3 
2.1 
4220 
4.9 
6.6 
50 
2.0 
1.6 
. 
5 
6 
6 
3 
1 
7 
5 
6 
1 
2 
6 
6 
1 
1 
FX 
FX/B 
FX/B 
FX 
FX 
FX 
FX 
FX/B 
FX 
Cap 
FX 
FX/B 
FX 
FX 
- 
- 
- 
6 
- 
1 
0 
- 
- 
0 
2 
- 
- 
- 
0 
2 
0 
 0 c 
0 
- 
0 
0 
0 
0 
0 
0 
0 
5c 
 0 
2 
1 
¯c 
0 
0 
0 
0 
1 
¯b 
¯b 
0 
1 
¯ c 
0 
6 
0 
¯c 
- 
0 
0 
0 
0 
¯b 
¯b 
0 
0 
¯ c 
No 
YesR 
Yes 
¯c 
No 
No 
No 
No 
No 
¯b 
¯b 
No 
No 
¯ c 
 ARM 1, ALPPS group; ARM 2, Single stage liver resection; Sync, synchronous colorectal liver metastases 
(CRLM); n, number of CRLM lesions; size, diameter of the largest CRLM; CEA, carcinoembryonic antigen; # 
Chemo, number of chemotherapy cycles before surgery; Type of chemo, FX FOLFOX, FR FOLFIRI, F/B 
FOLFOX and Bevacizumab, and Cap; Capecitabine. ¯ withdraw from the study: ¯a Different tumour biology, ¯b 
Associated chemotherapy toxicity, ¯c Tumor progression. d Insufficient blood sample, R recurrence and cancer 
related-death. 
ARM1, Time points blood samples ALPPS: # 1, Pre-Chemotherapy; # 2 Post-Chemotherapy; # 3a, Inter-Stage 
ALPPS, # 3b, Post- 2 Stage, # 4, Follow up. 
ARM2, Time points blood samples Single liver resection: # 1, Pre-Chemotherapy; # 2, Post-Chemotherapy; # 
3, Post-Liver resection; # 4, Follow up. 
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Figure 18. Comparison of Circulating tumor cells (CTC) status after chemotherapy (time-
point 2) and after liver resection (time-point 3a and 3b).  CTC status was available in 17 
patients that underwent for liver resection (7 in ARM-1, and 10 in ARM-2).  After stage 1 
ALPPS, two patients had CTC positive status (1-2 cells). Among the 6 patients with CTC 
status after 2 stage ALPPS, none of the patients with prior CTC negative status were found 
positive after completed both stages. On the other hand, from the 10 patients in AMR-2 
with CTC status after completed single stage resection, 4 patients were found with CTC 
positive status. Number of CTC and status (positive or negative) (y-axis). Time-point of 
blood sample collection for (x-axis).  Open circles represent ARM-1, whereas open squares 
ARM-2.  
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The presence of CTCs was evaluated at follow-up (1-2 months after surgery) in the 
16 patients with CTC status available. Of the seven patients in Arm 1, one patient who had 
positive CTCs after surgery remained positive at follow-up (1 cell). Of the 4 patients in 
Arm 2 with positive CTCs after liver resection, only one (12.5%) patient remained with 
positive CTC status during follow-up assessment (1-6 cells), p=0.999. In both cases where 
CTC positive status remained at follow-up (one patient in each Arm), these patients 
developed tumor recurrence, p=0.0083 (Figure 19).  Among the 16 patients with CTC 
status available at follow-up, eleven (69%) with negative CTC status were found alive 
without recurrence and three (19%) patients died. Two (12%) patients with positive CTC 
status were found with recurrence and cancer related-death, p=0.0249 (Table 6). Of the 
five deaths in the present study, three (43%) deaths were in Arm 1 and two (20%) were in       
Arm 2, p=0.592. 
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Figure 19. Circulating tumor cells (CTC) assessment after surgery and follow-up. Number of CTC 
and status (positive or negative) (y-axis). Time-point of blood sample for both groups (Post-surgery, 
and Follow-up) (x-axis). CTC status was available in 16 patients after surgery (circles), open circles; 
negative CTC, whereas, blue circles; positive CTC, (1-2 cells). At follow up, CTC status was 
available in 15 patients, open squares; negative CTC and recurrence free, while, purple triangle, 
positive CTC with recurrence (1-6 cells). 
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4.3. MAIT Cells  
 4.3.1.  MAIT cells frequency differences between healthy volunteer’s and 
colorectal liver metastases patients. 
Initially, to assess whether our population with metastatic cancer presents with a 
different frequency of MAIT cells, we decided to compare our colorectal liver metastatic 
population with a healthy volunteer. We observed that our patients with CRLM had a 
reduced frequency of PBMCs a mean frequency of 3.3% MAIT cells was found, while the 
healthy volunteers had a mean of 5.3%. (Figure 20a). This observation was later verified 
by MR1Tet staining (Figure 20b). Moreover, we compared the frequency of MAIT cells in 
the healthy liver population with the frequency of MAIT cells within the tumour in our 
CRLM population.  We found a generalized trend towards a reduction in the frequency of 
MAIT cells within the tumour, 28% vs 21%, however, this difference did not reach 
statistical significance (p = 0.073) (Figure 20c,d). 
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Figure 20 a 
 
 
 
 
 
 
 
 
 
Figure 20 b 
 
Figure 20 a-b. Graphics comparing the frequency of MAIT cells in the peripheral blood (PBMCS) 
among healthy 13 volunteers, and CRLM patients. A series of representative dot-plots depicting two 
equivalent gating strategies for identifying MAIT cells by CD3+Va7.2+CD161++ or 5-OP-RU MR-1tet. 
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Figure 20 c 
 
 
 
 
 
 
 
 
 
Figure 20 d 
 
 
 
Figure 20 c-d. Graphics describing the frequency of MAIT cells in the healthy liver volunteers, and 
tumor from CRLM patients. A series of representative dotplots depicting two equivalent gating strategies 
for identifying MAIT cells by CD3+Va7.2+CD161++ or 5-OP-RU MR-1tet.  
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4.3.2. Immunological differences between ALPPS group and single stage live 
resection. 
To assess whether the liver in the patients undergoing ALPPS (ARM 1) with CRLM 
remains immunologically competent, we evaluated the frequency of MAIT cells among 
both groups. Thus, we analyzed the frequency of MAIT cells from the total CD3+ within 
the peripheral blood (PBMCs), liver, and tumor. Samples were taken during the liver 
resection, as described previously (Figure 15-16). Among the 17 patients underwent for 
liver resection, 7 blood samples were available in ARM 1, whereas, 9 blood samples were 
available in ARM 2 for comparison. We found comparable frequency of MAIT cells in 
peripheral blood in both groups. Patients in ARM 1 had a mean frequency of 2.5% MAIT 
cells while the patients in ARM 2 had a mean frequency of 2.7 %, p= 0.870. (Figure 21) 
Furthermore, we evaluated the frequency of MAIT cells in the liver, as well as the 
tumor. Interestingly, there was a trend towards an increase in MAIT cells in the ARM 1 
within the liver (28 % vs 17.42%), however, this difference was not statistical significance 
(p=0.067), (Figure 22). Then, we observed the frequency of MAIT cells within the tumor. 
ARM 1 had a mean frequency of 17.42%, while, ARM 2 had a mean of 10.42 %, p=0.308. 
(Figure 23). Altogether, we evaluated and compared whether the frequency of the MAIT 
cells was different among both groups (the three compartments), but no significant 
difference was observed, p=0.271. Figure.24 
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Figure 21. Graphic describing the frequency of MAIT cells in the peripheral blood 
(PBMCs) in ARM-1 and ARM 2.  
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Figure 22. We evaluated the frequency of MAIT cells in the liver in ARM-1 and ARM-2 
of CRLM patients.  
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Figure 23. Graphic describing the frequency of MAIT cell within the tumor in 
ARM-1 and ARM 2 of CRLM patients. 
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Figure 24.  Graphic describing the frequency of MAIT cells in: the peripheral blood, liver, 
and tumor, between ARM-1 and ARM-2. No significance difference regarding the frequency 
of MAIT cells was observed, p=0.271.  
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4.3.3. Immunological competency of the liver after chemotherapy treatment 
Having noted a large degree of variability in the frequency of MAIT cells, we 
wondered what impact the perioperative chemotherapy regimen was having on the 
frequency and functionality of MAIT cells. With the majority of patients receiving either 
single regimen of chemotherapy with FOLFOX, or combined chemotherapy regimen with 
FOLFOX plus bevacizumab (Table 2), thus, we categorized patients based on the regimen 
of chemotherapy and evaluated the impact of the number of cycles they received on the 
frequency of MAIT cells. To evaluate this, we grouped patients as follow: 1) those that 
received FOLFOX (9 patients); 2) those that received FOLFOX + bevacizumab (Avastin) 
(8 patients); and 3) a group that received no chemotherapy (5 patients). 
Although there was a slight upward trend in the patients who received FOLFOX 
alone, there was no correlation between the number of cycles received and the frequency 
of MAIT cells in blood (PBMCs), Hepatic MAIT cells (HMNCs), or tumor tissue. (Figure 
25a) In contrast, there was a strong negative correlation between the cycle number and 
frequency of MAIT cells in the peripheral blood and healthy liver tissue of patients treated 
with FOLFOX + bevacizumab (PBMC: r2 = 0.944, p = 0.0057; Liver r2 = 0.915, p = 0.011) 
(Figure 25b). While a similar trend was observed in the tumor, this did not reach statistical 
significance (r2 = 0.73, p = 0.067) (Figure 25b). 
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Figure 25a-25b. The frequency of MAIT cells depicted compared to the number of cycles of 
Folfox received (Figure 25a), and Folfox and bevacizumab received (Figure 25 b). r2 and p 
values were generated by Pearson analysis. Analyzes in the PBMCs, liver (HMNCs), and tumor 
was performed. Frequency of MAIT cells (y- axis), number of cycles (x-axis) 
 
FOLFOX	GROUP	
	FOLFOX	+	BEVACIZUMAB	
(AVASTIN)	GROUP	
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4.3.3.1. Perioperative chemotherapy fundamentally alters MAIT cell 
populations on CRLM patients. 
Given the influence of the perioperative chemotherapy on the frequency of MAIT 
cells, and high variability of activation observed following stimulation,                                          
both inside, and outside the tumor. Interestingly, while the frequency of MAIT cells varied 
depending on the perioperative chemotherapy regimen in the peripheral blood and liver, 
the responsiveness to stimulation (rIL-12 + rIL-18, SEB, and Klebsiella lystate) was highly 
similar in each case (Figure 26 A-C). Moreover, the degree of responsiveness of MAIT 
cells within the tumor was highest in the group that received FOLFOX, with individuals 
who did not receive chemotherapy showing low levels of activation, and the those who 
received FOLFOX + Avastin showing virtually no responsiveness (Figure 26 C). 
Unexpectedly, while not significant, both chemotherapy regimens appeared to enhance the 
responsiveness of MAIT cells to stimulation with rIL-12 combined with rIL-18, as noted 
by the general increase in IFN-g by peripheral blood and liver MAIT cells  (Figure 26 A 
and B). While a number of individuals that received FOLFOX alone showed some degree 
of responsiveness in the tumor, in contrast, MAIT cells within the tumor (with only one 
exception) of those who received FOLFOX + bevacizumab demonstrated a complete lack 
of a response (Figure 26 C). Interestingly, this patient was the only individual to receive 
FOLFOX + Avastin that did not achieve any tumor necrosis, which was typically greater 
than 75% (data not shown). While this provides a likely explanation for the increased 
responsiveness in this individual, it remains to be seen what impact tumor necrosis has on 
the activation or survival of MAIT cells. 
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Figure 26 A-C. Differential effect of chemotherapy on the function of MAIT cells in 
CRLM patients. 
Figure 26 A-C. Describes how patients who had received no chemotherapy, Folfox alone, or Folfox +bevacizumab responded 
to stimulation with a panel of MAIT cell mitogens. (A) Left - the frequency of IFN-g production by PBMC MAIT cells in 
response to medium, rIL-12 +rIL-18, SEB, or Klebsiella lysate. Right – The frequency of PBMC MAIT cells producing IFN-g 
in response to  rIL-12 +rIL-18 is depicted compared to the number of cycles of Folfox or Folfox + bevacizumab  received; (B) 
Left - the frequency of IFN-g production by HMNCs MAIT cells in response to medium, rIL-12 +rIL-18, SEB, or Klebsiella 
lysate. Right – The frequency of HMNCs MAIT cells producing IFN-g in response to  rIL-12 +rIL-18 is depicted compared to 
the number of cycles of Folfox or Folfox + bevacizumab  received; (C) Left - the frequency of IFN-g production by tumor 
MAIT cells in response to medium, rIL-12 +rIL-18, SEB, or Klebsiella lysate. Right – The frequency of tumor MAIT cells 
producing IFN-g in response to rIL-12 +rIL-18 is depicted compared to the number of cycles of Folfox or Folfox + bevacizumab 
received. 
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CHAPTER 5 
5. DISCUSSION 
5.1. ALPPS 
ALPPS has emerged as a novel surgical approach with the potential to improve the 
likelihood of resectability, specifically in those patients with extensive cancer disease and 
a small FLR. The two major ALPPS advantages are: rapid liver kinetic growth, and surgical 
complete resection of all disease compared to the conventional two-staged hepatectomy 
with PVE. (70)  
These proposed advantages of ALPPS have been counterbalanced by reports of high 
perioperative morbidity and mortality. The first published cohort described a 12% 
perioperative mortality rate (78), with other studies reporting similarly high perioperative 
mortality as well as severe morbidity in up to two-thirds of patients (79). Our single-center 
experience with ALPPS demonstrates consistently acceptable morbidity and no 
perioperative mortality throughout the study period. Our group has previously published 
an early experience with ALPPS, demonstrating no 90-day mortality in a pilot series of 14 
patients (80). In this short cohort, we again report no 90-day mortality in 7 patients, with a 
66% minor complication (Clavien-Dindo £ II) rate.  
 
5.2. Circulating tumor cells “CTCs” 
Circulating tumour cells have been shown to represent the concentration of cancer 
cells in the blood circulation.(81,82) Furthermore, the presence of ³3 CTCs has been 
associated with poor prognosis in patients with metastatic colorectal cancer. (81–83) 
Therefore, the research community has investigated their utility to serve as potential 
surrogate markers for early treatment response, by associating their presence and 
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elevation with disease recurrence or progression, with promising results. (83,84) 
Accordingly, in our current investigation, we  chose it as an evaluation tool to assess if the 
rapid and extensive hypertrophy that occurs during the ALPPS procedure for treatment of 
colorectal liver metastasis results in increased tumor cells dissemination and disease 
progression. 
We evaluated the positivity and levels of circulating tumour cells at different time-
points during the treatment. After completion of chemotherapy the presence of CTCs was 
assessed, and of the two patients with positive CTCs, the one who had ³3 CTCs was 
withdrawn from the study due to disease progression. This finding correlates with other 
reports and confirms the prognostic value for disease progression at this CTC cut-
off.(61,82) Moreover, CTCs were evaluated at the time of surgery (after first and second 
stage ALPPS) and compared with the control group (single stage major liver resection) to 
whether rapid hypertrophy results in tumor cells dissemination. The present results show 
that intraoperative mobilization of the liver and tumor, portal vein ligation, and liver 
partition with subsequently accelerated, and extensive liver hypertrophy, do not release or 
increase the CTCs after first and second stages of ALPPS, based on no significant 
difference in CTC compared with the control group. Since the 2 Arms were comparable 
with respect to the tumour load, these results should be considerable. However, no recent 
report has evaluated ALPPS at such situation that can reinforce and validate our 
information.  
Two staged hepatectomy with PVE has been used as an standard procedure to 
provide increased hypertrophy in patients with insufficient FLR requiring extensive liver 
resection. However, 20-30% of the patients do not reach the second staged due to tumor 
progression.(26) Interesting observations were made by a group of Norway (2), when CTCs 
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were assessed at surgery after two-staged liver resection with PVE in CRLM patients, it 
was observed that levels of CTCs where higher after the second staged, and these patients  
has worse DFS and OS in their population of study. Contrary to their findings, our results 
showed that ALPPS might provide better outcomes and less tumour cell dissemination. 
This might be explained by the shorter period of inter-staged waiting time, 7-10 days for 
ALPPS, compared with the 6-8 weeks during the classical two-staged hepatectomy with 
PVE, which could increase the time for tumor cell growth. (85–87) 
In our study, we also evaluated the presence of CTCs at 1-2 months’ follow-up post-
surgery, observing that all patients that remained with negative CTC status did not present 
with tumour recurrence, whereas the two patients who had showed positive CTCs had 
detectable recurrence. Interestingly, both remained positive during all time-points of the 
study. Furthermore, both patients with persistence and positivity of CTCs had cancer-
related death. This interesting association supports what other groups have reported in other 
types of cancers, (88) and suggests that persistence of positivity of circulating tumour cells 
might have  an impact on prognosis and patient outcomes. 
Another important observation in our results is related to the levels of CTCs. 
Whereas others groups have reported a cut-off  for better or worse outcomes (<3 or ³3 CTC 
in a 7.5 mL CTC/blood sample blood sample)(60,82). We observed that the presence and 
persistence of ³1 circulating tumour cells was correlated with worse prognosis. This 
indicates that, an ideal cut-off in metastatic colorectal cancer remains undetermined.  
In conclusion, in our present investigation detection of CTC serves as an important 
tool of prognostic value in patients undergoing for ALPPS for colorectal liver metastasis. 
These findings suggest firstly that accelerated and extensive hypertrophy was not 
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associated with more release of cancer cells and subsequently disease progression. 
Secondly, persistence and positivity of CTC at follow-up was significantly associated with 
disease progression. Nevertheless, due the small sample size and short follow-up, our 
results should be taken carefully. Further follow-up combined with serial analysis of CTCs 
should be considered for future investigation. 
5.3.  MAIT cells  
The ALPPS approach results in an accelerated and extensive hypertrophy of the 
FLR. However, limited evidence exists regarding the immunological competence of the 
FLR, particularly in patients with CRLM. The liver represents a unique immunological 
organ dominated by innate-like T lymphocytes. Recently, it has been shown that a mucosa-
associated invariant T cell population comprise 30%-50% of the total hepatic T 
lymphocytes. (42,45) MAIT cells are innate-like T lymphocytes that express the invariant 
TCRa (iTCRa) chain TRAV1-2-TRAJ33 (Vα7.2-Jα33 in humans) (89,90) and produce a 
plethora of pro- and/or anti-inflammatory cytokines (e.g., IFN-g, TNF-a, IL-17, IL-4, and 
IL-10) and various granzymes (A, B, K ,and M) when activated (91,92).  Given this 
particularity of MAIT cells, their high proportion within the liver microenvironment, and 
their potential role during the liver immune response, thus, we wondered whether their 
frequency and functionality was affected during ALPPS and perioperative chemotherapy. 
Despite their abundance both in the liver and at other mucosal sites, the role of 
MAIT cells in tumor surveillance remains largely unknown. Initially, to elucidate the role 
of MAIT cells in CRLM patients, we compared our CRLM patients with a healthy group 
of volunteers. We evaluated the MAIT cells frequency from the total CD3+ PBMCs, and 
their capacity to be activated by a panel of agonists in both groups. Interestingly, and in 
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contrast to the findings of other studies, in which the frequency of the MAIT cells in the 
peripheral blood of cancer patients did not change (93), we observed a significant reduction 
in MAIT cells frequency in the peripheral blood. Moreover, we observed a trend towards a 
reduction in the frequency of MAIT cells within the tumor.  
Observing this variability of the frequency of the MAIT cells, we wondered if the 
MAIT cells frequency exhibits different proportion in the ALPPS group. In a recent ALPPS 
cohort published  by our group (77), we demonstrate that the ALPPS liver appears to 
maintain its immune distribution, and that the liver cell composition of the FLR during the 
extensive and accelerated hypertrophy remains constant. Also, we found the liver cell 
populations proportion including CD4+ T cells, NKT cells, B cells, Kupffer cells, and 
including the MAIT cells increased significantly. In our current investigation, we focused 
on MAIT cells, and found that MAIT cells frequency in the peripheral blood (PBMCs) 
remains similar, but their proportion in the liver showed a trend towards increasing 
compared with the control group. These findings enhance, and validate our prior 
investigation(77), where we concluded that, while accelerated and extensive hypertrophy 
occurs within the FLR in the ALPPS population, an expansion of hepatic immune cells 
results as well. 
 Altogether, MAIT cell frequency in the liver of CRLM population is reduced 
compare with the healthy volunteers, but higher in those who underwent an ALPPS 
resection. This might be explained by the immune system activation, as a consequence of 
the inflammatory mechanism of the ALPPS resulting in rapid hypertrophy of the FLR, 
therefore suggesting an homogeneous immune cell restoration.  
Furthermore, although we observed an increase in MAIT cells frequency in the liver 
in the ALPPS group, we observed a suppression in their frequency within the tumour in 
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both groups, thus, we wondered whether this variability may be due the influence of the 
perioperative type of chemotherapy. As such, we aimed to determine whether the different 
type of regimens had an impact on the frequency and functionality of MAIT cells, both 
inside and outside the tumor. We observed a slight upward trend in the frequency of MAIT 
cells in the patients who received FOLFOX alone, but no correlation between the number 
of cycles received or the frequency of MAIT cells in PBMCs, liver, or tumor tissue was 
found.  On the other hand, a strong negative correlation between the cycle number and 
frequency of MAIT cells in the peripheral blood and healthy liver tissue of patients treated 
with FOLFOX + bevacizumab was observed. 
Our observation with respect to the association of responsiveness of the immune 
response with FOLFOX therapy is similar to what has been reported by other authors 
(94,95). During the latest report from the randomised control trial EORTC in 2015 (94), 
whether the immune response in CRLM was influenced by systemic therapy was 
investigated and was related with patient disease free survival. In particular, the 
investigators evaluated liver resection alone or with the addition of FOLFOX therapy. 
Interestingly, in the group treated with FOLFOX, they observed and increase in the CD3+ 
lymphocytes and mast cells inside the tumor, demonstrating a correlation between high 
CD3+ response and pathological response. This was also related to an improvement in the 
disease free survival. A similar association was also reported by Halama et al, 
demonstrating a highly density of CD3+, CD+8, and granzyme B+ T cells within the tumor 
margins of CRLM patients treated with FOLFOX therapy, and associated this with longer 
disease free and overall survival.(95)  
An explanation of how chemotherapy affects the immune response was offered by 
Zitovogel et al. Their hypothesis involves transitional mechanisms of lymphopenia, 
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followed by a high stimulation of more tumour infiltrating T-cells, thereby favoring 
chemokine attraction into the tumor, with subsequent tumor cell death. (94,96) 
In contrary to the findings in the FOLFOX, the combined regimen group 
experienced a decrease in MAIT cells frequency, and a lack of responsiveness after 
stimulation in those patients with more than 75 % of tumor necrosis. It is perplexing that 
the addition of bevacizumab a monoclonal antibody against a vascular endothelial growth 
factor (VEGF), could so drastically effect the frequency of MAIT cells. One explanation 
could be related to the regulation of the multidrug resistance gene 1 (MDR1), an ABC 
transporter known to provide MAIT cells with resistance to chemotherapy (44,93,97). 
Specifically, there have been reports that VEGF can induce the expression of MDR1 in 
various cell types (98). It remains plausible that MDRI expression by MAIT cells may be 
partially dependent on VEGF.  
Together, these results showed that chemotherapy affects the liver immune 
response, depending of the type of chemotherapy regimen received.  The findings suggest 
that FOLFOX therapy has immunostimulatory effects in the liver, while bevacizumab 
therapy leads to tumor necrosis with immunosuppressive side effects within the tumor. 
Each regimen seems to act in different pathway, and their therapeutics efficacy should be 
interpreted independently, giving the concept that chemotherapy should stimulate the 
immune response. Thus, the liver immune activation or suppression within the tumor may 
result underestimation of the regimen response.  
Although convincing, given the small sample size, a larger cohort is needed to 
validate these findings. Moreover, longer follow up is necessary to evaluated whether this 
variability in the responsiveness of the chemotherapy might have a prognostic impact. 
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